Interleukin-33 from oligodendrocytes sustains effector differentiation of tissue-resident CD8+ T cells and is a druggable target in CNS autoimmune disease
Nicolas Fonta, Nicolas Pagé, Bogna Klimek, Margot Piccinno, Giovanni Di Liberto, Sylvain Lemeille, Mario Kreutzfeldt, Anna Lena Kastner, Yusuf I. Ertuna, Ilena Vincenti, Ingrid Wagner, Daniel D. Pinschewer, Doron Merkler
This study identifies IL-33 from oligodendrocytes as a key regulator of self-reactive CD8+ T cell differentiation in CNS autoimmunity and shows its potential as a therapeutic target.
The Journal of Experimental Medicine · Mar 13, 2025Peer-reviewedImmunology